Marker Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $10 price target The company’s pipeline of non-genetically engineered T cell-based immunotherapies has the potential to overcome safety, efficacy, and scalability limitations of single-antigen targeted immunotherapy modalities including chimeric antigen receptor T cells, the analyst tells investors in a research note. The firm says Marker is advancing both autologous and allogeneic MAR-T cell therapies through clinical development as part of its wholly-owned pipeline. H.C. Wainwright believes MAR-T cell therapies position Marker as an emerging leader across the “competitive” space of cancer immunotherapy.